Experimental combo targets Hard-to-Treat cancers
NCT ID NCT04375267
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs—177Lu-DOTA-TATE (a radioactive therapy) and olaparib (a PARP inhibitor)—in 18 people with certain cancers like neuroendocrine tumors, thymoma, or mesothelioma that have a specific marker (somatostatin receptor). The goal was to see if the combination is safe and to find the best dose. The idea is that olaparib may make cancer cells more sensitive to the radiation from 177Lu-DOTA-TATE, potentially killing more tumor cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 177Lu-DOTA-TATE and olaparib
- What this could lead to
- If this works, it could point toward a more effective treatment for certain neuroendocrine tumors and other cancers that express somatostatin receptors.
- What could go wrong
- This is a very early Phase I trial with only 18 participants, focused on safety and dosing. It may not show significant benefit, and the combination could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL TRIAL, PHASE I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dept of Oncology
Gothenburg, 41345, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Which palliative care approach boosts quality of life in advanced lung cancer?
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Abdominal chemotherapy after surgery may improve mesothelioma outcomes